Evaluation of an IDH1m Inhibitor in Patients with IDH1-Mutated Malignancies and Hepatic or Renal Impairment

The primary objective is to evaluate the efficacy of an IDH1m inhibitor in individuals presenting with IDH1-mutated malignancies. This investigation is clinically significant for addressing neoplastic processes characterized by mutations in the isocitrate dehydrogenase 1 gene. The study population includes those with newly diagnosed or previously treated malignancies, specifically considering the presence of hepatic impairment or renal impairment.

This study involves 12 patients with IDH1-mutated malignancies that are either newly diagnosed or have been previously treated. The study population includes both males and females within age ranges 3 and 4. The sponsor did not provide information regarding specific lifestyle considerations or detailed inclusion and exclusion criteria.

This Phase 3 clinical trial evaluates the efficacy and safety of an IDH1 inhibitor in individuals diagnosed with IDH1-mutated malignancies, specifically those with concurrent hepatic impairment or renal impairment. The study utilizes a randomized, controlled design. The research sequence commences with a screening visit to assess eligibility based on predefined clinical criteria. Following enrollment, participants undergo periodic follow-up visits to monitor therapeutic response and safety parameters. The protocol concludes with an end-of-study visit. Total participant involvement is determined by individual clinical progress and study requirements. Early termination from the trial may occur due to specific safety concerns or clinical withdrawal criteria.

The assessment of efficacy in this phase 3 clinical trial focuses on patients with IDH1-mutated malignancies. The protocol aims to evaluate therapeutic outcomes in both newly diagnosed and previously treated populations.